Statistical Hurdle Overshadows Valneva Vaccine Efficacy Data

Valneva and Pfizer's Lyme disease vaccine showed strong efficacy but missed its primary statistical endpoint, causing Valneva's stock to drop ~40% as Pfizer plans regulatory submission.

A promising Lyme disease vaccine candidate demonstrating over 73% efficacy has paradoxically triggered a steep decline in the developer's share price. The market's reaction highlights how statistical requirements in clinical trials can outweigh even strong efficacy results.

Valneva, in partnership with Pfizer, announced that its Phase 3 VALOR trial for the VLA15 vaccine did not meet its primary endpoint. The setback was not due to a lack of vaccine effectiveness but rather a failure to achieve the predefined statistical threshold. The 95% confidence interval in the initial analysis fell below the required lower bound. This occurred because the incidence of Lyme disease during the study period was lower than projected. With only a limited number of cases among the 9,437 participants, the trial lacked the statistical power to conclusively hit its target.

Pfizer Forges Ahead with Regulatory Submission

Despite the primary endpoint miss, a second pre-specified analysis yielded an efficacy rate of 74.8%, with a confidence interval lower bound above 20%. This data appears sufficient for Pfizer to proceed with plans to submit a Biologics License Application (BLA) to U.S. regulators. Valneva has indicated a potential market launch for the vaccine in the second half of 2027.

The impact of the news diverged sharply between the two partners. For Pfizer, VLA15 represents one project among a vast pipeline. For Valneva, however, it was viewed as the central driver for future growth. This disparity was reflected in their stock performance. While Pfizer shares showed little pre-market movement, Valneva's equity plummeted approximately 40%, hitting an intraday low around €2.54 before closing near €2.90.

Approval Pathway Open Amid Lingering Uncertainty

Analysts at RBC Capital Markets estimate the vaccine could still achieve peak sales potential of around $525 million. The underlying market need is significant, with approximately 476,000 Lyme disease cases diagnosed annually in the United States and a further 132,000 across Europe.

Prior to the trial data release, the consensus analyst price target for Valneva stood at €6.95—more than double the current trading level. The extent to which financial institutions revise their valuation models following the missed primary endpoint is likely to influence the stock in the coming sessions. Pfizer's decision to move forward with a regulatory filing remains the primary counterbalance to the negative sentiment.

The situation underscores a complex reality in biopharma investing: a drug can show compelling medical promise yet stumble on the meticulous statistical benchmarks required for regulatory success, with immediate and severe consequences for smaller developers.